As per DelveInsight, the global Immunomodulators market is estimated to grow at a CAGR of 5.19% during the forecast period from 2023 to 2028. The rising
In the second-line setting of head and neck cancer, metronomic triple therapy outperformed clinician choice chemotherapy in both progression-free survival and overall survival.
During the forecast period 2023 to 2033, the Rosai-Dorfman Disease (RDD) Therapeutics market is expected to grow at a value of 6.9% CAGR, according to Future Market Insights. By the year 2033, the global market for Rosai-Dorfman Disease (RDD) Therapeutics is expected to rise up to a market valuation of US$ 839.95 Mi.